# PACIRA BIOSCIENCES, INC. (PCRX) · Edgar & Edgarette company card

> Pacira Biosciences, Inc. (PCRX) grew revenue 3.6% in FY2025 to $726 million, operating margin 2.6% against a -3.8% median for pharmaceutical preparations, equity 54.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1396814 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/PCRX) · [JSON](https://www.pops4.com/boards/company/PCRX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $726M |
| Revenue growth, 1 year | 3.6% |
| Revenue growth per year | 7.6% |
| Operating margin | 2.6% (prior year -10.5%) |
| Net margin | 1.0% |
| Operating cash flow | $152M |
| Capital spending | $15M |
| Free cash flow | $137M |
| Cash | $159M |
| Long-term debt | $372M |
| Total assets | $1.3B |
| Total equity | $693M |
| Equity ÷ assets | 54.8% |
| Return on equity | 1.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 3.08 (safe zone)
- Piotroski F: 8 of 9 (strong)
- Beneish M: -2.93 (below the −1.78 line)
- Health Harbor boat: Sound ship · one warning sign · filed debt accelerated or triggered in the last 12 months
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $726.4M (FY2025), total debt $372.2M. Experience: revenue up 3.6% on the year, up 7.6% a year over 4 years; operating margin 2.6%, up from -10.5%. Soundness: equity 54.8% of assets, return on equity 1.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $627.7M and $861.4M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $579.4M to $936.3M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 2.6% against a -3.8% median; growth 3.6% against 13.7%.

Range logged 2026-10-09, receipt b0fac3d45791d39d, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-11-17 ([filing](https://www.sec.gov/Archives/edgar/data/1396814/000114036126044354/0001140361-26-044354-index.htm))
- Item 2.04 Debt accelerated or triggered: 1, latest 2026-11-17 ([filing](https://www.sec.gov/Archives/edgar/data/1396814/000114036126044354/0001140361-26-044354-index.htm))
- Item 5.02 Director or officer change: 3, latest 2026-11-17 ([filing](https://www.sec.gov/Archives/edgar/data/1396814/000114036126044354/0001140361-26-044354-index.htm))

## Recent filings

- 8-K · filed 2026-11-17 · 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.04 Triggering Events That Accelerate a Financial Obligation; 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 3.03 Material Modifications to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure or Election of Directors; Appointment of Officers; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1396814/000114036126044354/0001140361-26-044354-index.htm)
- 8-K · filed 2026-11-12 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1396814/000114036126043437/0001140361-26-043437-index.htm)
- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1396814/000162828026071136/0001628280-26-071136-index.htm)
- 8-K · filed 2026-11-05 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1396814/000162828026071129/0001628280-26-071129-index.htm)
- 8-K · filed 2026-10-08 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1396814/000110465926114571/0001104659-26-114571-index.htm)
- 10-Q · filed 2026-08-04 · [filing](https://www.sec.gov/Archives/edgar/data/1396814/000162828026052635/0001628280-26-052635-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001396814.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1396814

## Cite

POPS4, Edgar & Edgarette: PACIRA BIOSCIENCES, INC. (PCRX) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/PCRX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

